Log in

NYSE:EWEdwards Lifesciences Stock Price, Forecast & News

$69.19
+0.19 (+0.28 %)
(As of 07/3/2020 12:12 PM ET)
Add
Compare
Today's Range
$68.80
Now: $69.19
$70.23
50-Day Range
$67.13
MA: $109.57
$224.72
52-Week Range
$51.51
Now: $69.19
$82.55
Volume2.04 million shs
Average Volume3.32 million shs
Market Capitalization$42.87 billion
P/E Ratio39.69
Dividend YieldN/A
Beta0.86
Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States and internationally. It offers transcatheter heart valve therapy products comprising transcatheter aortic valve replacement, and transcatheter mitral and tricuspid therapies for the nonsurgical replacement of heart valves. The company also provides surgical heart valve therapy products, such as pericardial valves for aortic and mitral surgical valve replacement; aortic heart valves; annuloplasty rings; and cardiac cannula devices, as well as various procedure-enabling platforms to advance minimally invasive surgery. In addition, it offers critical care products, such as hemodynamic monitoring systems to measure a patient's heart function in surgical and intensive care settings; pulmonary artery catheters; Oximetry Central Venous catheters, as well as clinical monitoring platforms that display a patient's physiological status; Acumen Hypotension Prediction Index, an advanced algorithm that indicates the likelihood of a patient developing hypotension; and disposable pressure monitoring devices and closed blood sampling systems to protect patients and clinicians from infection. The company distributes its products through direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1999 and is headquartered in Irvine, California.
Read More
Edwards Lifesciences logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.3Community Rank: 2.9Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 1.3 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.69 out of 5 stars


Industry, Sector and Symbol

Industry Surgical appliances & supplies
Sub-IndustryHealth Care Equipment
SectorMedical
CUSIP28176E10
Phone949-250-2500

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$4.35 billion
Cash Flow$2.04 per share
Book Value$6.63 per share

Profitability

Net Income$1.05 billion

Miscellaneous

Employees13,900
Market Cap$42.87 billion
Next Earnings Date7/23/2020 (Confirmed)
OptionableOptionable

Receive EW News and Ratings via Email

Sign-up to receive the latest news and ratings for EW and its competitors with MarketBeat's FREE daily newsletter.

Edwards Lifesciences (NYSE:EW) Frequently Asked Questions

How has Edwards Lifesciences' stock been impacted by COVID-19 (Coronavirus)?

Edwards Lifesciences' stock was trading at $65.79 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, EW stock has increased by 5.2% and is now trading at $69.19. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Edwards Lifesciences?

23 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Edwards Lifesciences in the last year. There are currently 1 sell rating, 7 hold ratings and 15 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Edwards Lifesciences.

When is Edwards Lifesciences' next earnings date?

Edwards Lifesciences is scheduled to release its next quarterly earnings announcement on Thursday, July 23rd 2020. View our earnings forecast for Edwards Lifesciences.

How were Edwards Lifesciences' earnings last quarter?

Edwards Lifesciences Corp (NYSE:EW) released its quarterly earnings data on Thursday, April, 23rd. The medical research company reported $0.50 EPS for the quarter, topping the Thomson Reuters' consensus estimate of $0.43 by $0.07. The medical research company earned $1.13 billion during the quarter, compared to analysts' expectations of $1.03 billion. Edwards Lifesciences had a net margin of 24.71% and a return on equity of 31.83%. The company's quarterly revenue was up 13.7% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.44 EPS. View Edwards Lifesciences' earnings history.

When did Edwards Lifesciences' stock split? How did Edwards Lifesciences' stock split work?

Edwards Lifesciences's stock split before market open on Friday, May 29th 2020. The 3-1 split was announced on Thursday, May 7th 2020. The newly issued shares were payable to shareholders after the market closes on Monday, May 18th 2020. An investor that had 100 shares of Edwards Lifesciences stock prior to the split would have 300 shares after the split.

What guidance has Edwards Lifesciences issued on next quarter's earnings?

Edwards Lifesciences issued an update on its FY20 earnings guidance on Thursday, April, 23rd. The company provided earnings per share (EPS) guidance of $4.75-5.25 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $4.46. The company issued revenue guidance of $4.00-4.50 billion, compared to the consensus revenue estimate of $4.08 billion.

What price target have analysts set for EW?

23 Wall Street analysts have issued 1-year price targets for Edwards Lifesciences' shares. Their forecasts range from $51.67 to $100.00. On average, they expect Edwards Lifesciences' share price to reach $82.77 in the next year. This suggests a possible upside of 19.6% from the stock's current price. View analysts' price targets for Edwards Lifesciences.

Has Edwards Lifesciences been receiving favorable news coverage?

Headlines about EW stock have trended somewhat positive recently, InfoTrie Sentiment Analysis reports. The research group identifies positive and negative news coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Edwards Lifesciences earned a news impact score of 1.6 on InfoTrie's scale. They also gave media stories about the medical research company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the company's share price in the next few days. View the latest news about Edwards Lifesciences.

Who are some of Edwards Lifesciences' key competitors?

What other stocks do shareholders of Edwards Lifesciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Edwards Lifesciences investors own include NVIDIA (NVDA), Alibaba Group (BABA), salesforce.com (CRM), Walt Disney (DIS), Home Depot (HD), Visa (V), Adobe (ADBE), Mastercard (MA), QUALCOMM (QCOM) and CVS Health (CVS).

Who are Edwards Lifesciences' key executives?

Edwards Lifesciences' management team includes the following people:
  • Mr. Michael A. Mussallem, Chairman & CEO (Age 66)
  • Mr. Scott B. Ullem, Corp. VP & CFO (Age 52)
  • Mr. Donald E. Bobo Jr., Corp. VP of Strategy & Corp. Devel. (Age 57)
  • Mr. Robert W. A. Sellers, Principal Accounting Officer, VP & Corp. Controller
  • Dr. Todd J. Brinton, Corp. VP of Advanced Technology & Chief Scientific Officer

What is Edwards Lifesciences' stock symbol?

Edwards Lifesciences trades on the New York Stock Exchange (NYSE) under the ticker symbol "EW."

Who are Edwards Lifesciences' major shareholders?

Edwards Lifesciences' stock is owned by a number of institutional and retail investors. Top institutional investors include M&R Capital Management Inc. (0.00%). Company insiders that own Edwards Lifesciences stock include Catherine M Szyman, Donald E Bobo Jr, Donald E Bobo, Jr, Huimin Wang, Jean-Luc M Lemercier, Larry L Wood, Michael A Mussallem, Robert WA Sellers, Schack Wesley W Von, Scott B Ullem and William J Phd Link. View institutional ownership trends for Edwards Lifesciences.

Which institutional investors are buying Edwards Lifesciences stock?

EW stock was purchased by a variety of institutional investors in the last quarter, including M&R Capital Management Inc.. View insider buying and selling activity for Edwards Lifesciences.

How do I buy shares of Edwards Lifesciences?

Shares of EW can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Edwards Lifesciences' stock price today?

One share of EW stock can currently be purchased for approximately $69.19.

How big of a company is Edwards Lifesciences?

Edwards Lifesciences has a market capitalization of $42.87 billion and generates $4.35 billion in revenue each year. The medical research company earns $1.05 billion in net income (profit) each year or $1.86 on an earnings per share basis. Edwards Lifesciences employs 13,900 workers across the globe.

What is Edwards Lifesciences' official website?

The official website for Edwards Lifesciences is www.edwards.com.

How can I contact Edwards Lifesciences?

Edwards Lifesciences' mailing address is ONE EDWARDS WAY, IRVINE CA, 92614. The medical research company can be reached via phone at 949-250-2500 or via email at [email protected]

This page was last updated on 7/3/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.